2024-03-29T07:36:59Zhttps://scholarsbank.uoregon.edu/oai/requestoai:scholarsbank.uoregon.edu:1794/108422015-06-18T01:04:20Zcom_1794_3786com_1794_7561com_1794_7550col_1794_10840
Oregon Law Review : Vol. 88 No. 4, p.1053-1084 : The Evolution of a New Pleading Standard: Ashcroft v. Iqbal
Smith, Douglas G.
Bell Atlantic v. Twombly
Ashcroft v. Iqbal
Pleading standard
2010-11-23T23:32:46Z
2010-11-23T23:32:46Z
2010-11-23T23:32:46Z
2009
Article
0196-2043
http://hdl.handle.net/1794/10842
en_US
University of Oregon Law School
oai:scholarsbank.uoregon.edu:1794/108432015-06-18T00:59:15Zcom_1794_3786com_1794_7561com_1794_7550col_1794_10840
Oregon Law Review : Vol. 88 No. 4, p.1085-1138 : Physician-Assisted Suicide and Dementia: The Impossibility of a Workable Regulatory Regime
Mitchell, John B.
Physician-assisted suicide
Assisted suicide
Dementia
Part I of this Article explores the neurophysiological effects of
dementia on the interrelated processes of memory, cognition, and
language. The section then explains how the neurological damage
associated with dementia manifests in the daily life of the dementia
sufferer. Part II faces the myth of “the empty shell” head on—
exploring the myth, debunking it, and then explaining the need to
curb the self-fulfilling institutional dynamics of “malignant
positioning.” Finally, Part III directly confronts the impossibility of
creating a legal regime that can acceptably regulate PAS and
dementia.
2010-11-23T23:41:15Z
2010-11-23T23:41:15Z
2010-11-23T23:41:15Z
2009
Article
0196-2043
http://hdl.handle.net/1794/10843
en_US
University of Oregon Law School
oai:scholarsbank.uoregon.edu:1794/108452015-06-18T00:55:59Zcom_1794_3786com_1794_7561com_1794_7550col_1794_10840
Oregon Law Review : Vol. 88 No. 4, p. 1189-1220 : These Statements Have Not Been Approved by the FDA: Improving the Postapproval Regulation of Prescription Drugs
Page, Christopher R.
Pharmaceutical industry -- United States
United States. Food and Drug Administration
FDA
In light of the current regulatory climate, this Comment argues for
a new approach to the regulation of prescription drugs approved by
the FDA for general sale. The author proposes a reorganization of the
agency resulting in the creation of a division of the FDA that focuses
solely on actively making regulatory decisions regarding postapproval
pharmaceutical products. This new division should be granted the
power to effectively gather information and enforce regulations
against pharmaceutical companies without needing to consult with another agency or FDA division. The use of this power by a new
division would significantly ameliorate much of the public distrust
discussed previously.
2010-11-23T23:53:19Z
2010-11-23T23:53:19Z
2010-11-23T23:53:19Z
2009
Article
0196-2043
http://hdl.handle.net/1794/10845
en_US
University of Oregon Law School
oai:scholarsbank.uoregon.edu:1794/108412015-06-18T00:59:43Zcom_1794_3786com_1794_7561com_1794_7550col_1794_10840
Oregon Law Review : Vol. 88 No. 4, p. 963-1052 : Oregon’s New Choice-of-Law Codification for Tort Conflicts: An Exegesis
Symeonides, Symeon C.
Torts
Conflict of laws
Choice of law
On January 1, 2010, Oregon’s new choice-of-law codification for
tort conflicts went into effect.1 This pioneering statute is one
more example of Oregon’s well-established propensity and capacity
to innovate and to lead. The new statute is the first attempt to codify
this interesting but difficult subject in a common-law state in the
United States. This Article provides a section-by-section exegesis
of the new statute in an effort to assist courts and counsel in
interpreting and applying it.
2010-11-23T19:45:17Z
2010-11-23T19:45:17Z
2010-11-23T19:45:17Z
2009
Article
0196-2043
http://hdl.handle.net/1794/10841
en_US
University of Oregon Law School
oai:scholarsbank.uoregon.edu:1794/108442015-06-18T00:56:01Zcom_1794_3786com_1794_7561com_1794_7550col_1794_10840
Oregon Law Review : Vol. 88 No. 4, p.1139-1188 : The Graying of the American Manufacturing Economy: Gray Markets, Parallel Importation, and a Tort Law Approach
Grant, Joseph Karl
This Article examines the gray market or parallel
importation as it impacts
American manufacturers from three discrete legal perspectives: (1)trademark law, (2) customs law, and (3) copyright law. Further, this
Article explores in depth the case law in the United States that has
framed the gray market discussion. This Article concludes by
recommending that American manufacturers turn to tort law as a
solution to their gray market issues. Specifically, this Article
advocates for the use of the tort of intentional interference with
performance of contract by a third person as a means to combat the
problem of gray market or parallel importation of goods.
2010-11-23T23:45:53Z
2010-11-23T23:45:53Z
2010-11-23T23:45:53Z
2009
Article
0196-2043
http://hdl.handle.net/1794/10844
en_US
University of Oregon Law School